Steroid Refractory GVHD Clinical Trial
Official title:
Phase 2 Open Label Prospective Dose-Ranging Clinical Trial With Escalation and Expansion Cohorts to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease
This study is a Open Label Prospective Dose-Ranging Escalation and Expansion Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the secondary treatment of acute Graft-versus-Host Disease (aGvHD) in hospitalized patients who are steroid-refractory.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05017688 -
Prospective Interventional Study Exploring the Microbiota Recolonization in SR-GvHD Patients Receiving MaaT013
|
N/A | |
| Not yet recruiting |
NCT04289103 -
Evaluation of EFficacy and SaFEty of Leukotac (Inolimomab) in Pediatric Patients With SR-aGvHD
|
Phase 3 | |
| Recruiting |
NCT04769895 -
MaaT013 as Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients
|
Phase 3 | |
| Completed |
NCT04926194 -
Decidual Stromal Cells to Treat Graft-vs-Host Disease After Stem Cell Transplant for Myelodysplastic Syndrome/Myeloproliferative Neoplasm
|
Phase 2 | |
| Terminated |
NCT04070781 -
Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease
|
Phase 1 | |
| Completed |
NCT05663827 -
Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease
|
Phase 3 | |
| Terminated |
NCT01485055 -
Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease
|
Phase 2 | |
| Completed |
NCT05052385 -
ECP Combination Study
|
||
| Available |
NCT04768907 -
Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease
|